Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivity.

  title={Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivity.},
  author={Carlo C. Maley and Brian J. Reid and Stephanie Forrest},
  journal={Cancer epidemiology, biomarkers \& prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology},
  volume={13 8},
  • C. MaleyB. ReidS. Forrest
  • Published 1 August 2004
  • Medicine, Biology
  • Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Cells in neoplasms evolve by natural selection. Traditional cytotoxic chemotherapies add further selection pressure to the evolution of neoplastic cells, thereby selecting for cells resistant to the therapies. An alternative proposal is a benign cell booster. Rather than trying to kill the highly dysplastic or malignant cells directly, a benign cell booster increases the fitness of the more benign cells, which may be either normal or benign clones, so that they may outcompete more advanced or… 

Figures and Tables from this paper

Somatic evolution in neoplastic progression and cancer prevention

It is hypothesized that some of the cancer prevention trials fail because they select for clones that are resistant to the intervention and actually benefit those clones by suppressing their competitors.

Application of Evolutionary Principles to Cancer Therapy.

Treatment methods that attempt to understand and exploit intratumoral evolution to prolong response to therapy are reviewed, finding that treating metastatic cancers using the traditional strategy aimed at killing the maximum number of tumor cells is evolutionarily unsound.

Integrating evolutionary dynamics into cancer therapy

A variety of evolutionarily informed strategies designed to increase the probability of disease control or cure by anticipating and steering the evolutionary dynamics of acquired resistance are described.

Changing mutational and adaptive landscapes and the genesis of cancer.

Dispersal Evolution in Neoplasms: The Role of Disregulated Metabolism in the Evolution of Cell Motility

It is suggested that higher rates of cell metabolism lead to selection for motile cells in premalignant neoplasms, which may preadapt cells for subsequent invasion and metastasis, which has important implications for understanding the progression of cancer from less invasive to more invasive cell types.

Scales of Cancer Evolution: Selfish Genome or Cooperating Cells?

The cell state dynamics in cancer clones are interpreted as the risk diversifying strategy bet hedging, optimizing the balance between the exploitation and exploration of the cell state space, in analogy to the evolutionary optimization in a changing environment.

Towards Multidrug Adaptive Therapy

A cancer treatment case study is presented as a point of departure to illustrate three novel concepts to aid the design of multidrug adaptive therapies, which can trap tumor evolution in a periodic, controllable loop.

Lessons from applied ecology: cancer control using an evolutionary double bind.

It is proposed that long term outcome from any treatment strategy for invasive pests, including cancer, is not limited by evolution of resistance, but rather by the phenotypic cost of that resistance.

Evolutionary biology of cancer.




Exploring the Relationship between Neutral and Selective Mutations in Cancer

The agent-based model allows us to examine the interactions of mutations critical for the development of cancer that are either evolutionarily neutral or selective, and suggests that selective mutations facilitate theDevelopment of cancer, so that the more selective mutations necessary for the developed cancer, the greater the chance of developing it.

The clonal evolution of tumor cell populations.

Each patient's cancer may require individual specific therapy, and even this may be thwarted by emergence of a genetically variant subline resistant to the treatment, which should be directed toward understanding and controlling the evolutionary process in tumors before it reaches the late stage usually seen in clinical cancer.

An evolutionary model of carcinogenesis.

A quantitative model of carcinogenesis based on methods from population biology and game theory demonstrates normal cells in vivo occupy a ridge-shaped maximum in a well-defined tissue fitness

Increased cell division as a cause of human cancer.

Under this increased cell division model, the pathogenesis of cancer may result from molecular genetic errors induced during the process of cell division and from altered growth control of malignant or premalignant cells.

Model for the genetic evolution of human solid tumors.

The modeling studies suggest that the overrepresentation of individual oncogene-bearing chromosomes in aneuploid cell lines may require the activation of gene dose-dependent growth-promoting genes and is not likely to occur in cell lines in which at least two copies of each normal chromosome are required for cell survival.

Fate of clonal lineages during neoplasia and metastasis studied with an incorporated genetic marker.

The fate of clonal lineages in tumor formation and metastasis has been studied by genotypic marking of cells from three separate tumor lines of different malignant potential. Marking was accomplished

Drug resistance: Resisting arrest

The authors investigated the effect of the tumour suppressors Ink4a and Arf — which are encoded by the Cdkn2a locus — by crossing Eμ-myc mice with Arf mice and found that the loss of Ink4A provides a growth advantage to cancer cells.

Application of quantitative models from population biology and evolutionary game theory to tumor therapeutic strategies.

The mathematical models support therapeutic strategies that simultaneously alter several of the key parameters in the state equations and demonstrate that administration of cytotoxic therapies will create system dynamics more conducive to perturbations by biological modifiers.

Metapopulation dynamics and spatial heterogeneity in cancer

It is posited that the rules that apply to spatial ecology and explain the maintenance of diversity are also at work in tumors and may underlie tumor microheterogeneity.

Evolution of neoplastic cell lineages in Barrett oesophagus

The evolutionary relationships of non-random LOH, TP53 and CD KN2A mutations, CDKN2A CpG-island methylation and ploidy during neoplastic progression are determined and indicate that clonal evolution is more complex than predicted by linear models.